* Magenta Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 2 (estimated).
*
* Refinitiv's mean analyst estimate for Magenta Therapeutics Inc is for a loss of 19 cents per share.
* The one available analyst rating on the shares is "hold".
* The mean earnings estimate of analysts had fallen by about 24.2% in the last three months.
* Wall Street's median 12-month price target for Magenta Therapeutics Inc is $1, above its last closing price of $0.81.
This summary was machine generated July 31 at 16:00 GMT. All figures in US dollars unless otherwise stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。